U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C6H12O6
Molecular Weight 180.1559
Optical Activity ( + / - )
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PSICOSE, DL-

SMILES

OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO

InChI

InChIKey=BJHIKXHVCXFQLS-PUFIMZNGSA-N
InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3,5-9,11-12H,1-2H2/t3-,5-,6+/m1/s1

HIDE SMILES / InChI
D-Psicose (akaD-allulose) is a low energy monosaccharide found throughout nature in small quantities. t is a c-3 epimer of D-fructose and has 50% the sweetness of sucrose. Possible health benefits include improved insulin resistance, antioxidant enhancement and formation, and hypoglycemic controls. The use US-FDA lists psicose as generally recognized as safe (GRAS) and has approved its use as a food additive in a wide variety of products. Psicose is not generally metabolized and does not raise blood sugar levels above baseline after consumption. In addition, to use as a low-calorie sweetener, psicose has also been formally investigated as a dietary supplement to control obesity and pre-diabetic insulin insensitivities. Furthermore, D-psicose has shown the ability to inhibit the proliferation of ovarian cancer cells in vitro.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Growth inhibitory effect of D-allose on human ovarian carcinoma cells in vitro.
2005 Jul-Aug
D-Psicose inhibits the expression of MCP-1 induced by high-glucose stimulation in HUVECs.
2007 Jul 26
Influence of a rare sugar, d-Psicose, on the physicochemical and functional properties of an aerated food system containing egg albumen.
2008 Jun 25
Hypoglycemic health benefits of D-psicose.
2012 Feb 1
Rare sugar D-psicose protects pancreas β-islets and thus improves insulin resistance in OLETF rats.
2012 Sep 7
Patents

Sample Use Guides

Over 5 visits Healthy volunteers and volunteers with impaired fasting glucose consumed 1 of 5 beverages with 50 g sucrose and varying levels of D-psicose (0,2.5, 5, 7.5 and 10 g). Beverages were presented in a random order and the subject and investigator were blind to the composition of the beverage. Subjects maintained 24-hour dietary records prior to each visit and abstained from consuming any calories for 8 hours prior to the visit. Venous blood samples were collected prior to consuming the beverage and at 30, 60, 90, and 10 min after.
Route of Administration: Oral
Human ovarian adenocarcinoma cells (OVACAT-3) were maintained at 37 deg-C under an atmosphere of 5% CO2 in RPMI 1640 medium and supplemented with 10% fetal calf serum, 10 micro-g/mL insulin, 100 IU/mL penicillin, and 100 micro-g/mL streptomycin. Cell growth assay was initiated when the OVCAR-3 cells were in the logarithmic growth phase. Cells were seeded onto a 96-well plate with medium and cultured for 24 hours. Culture medium was refreshed including 50 mM of D-psicose. After 1 - 5 days, 10 micro L of MTT solution was added to each well and the plates incubated another 4 hours at 37 deg-C. The dose-dependent effect was further investigated by adding different concentrations of D-psicose (1, 5, 10, 20, 50 mM). The final MTT assay was performed after 1- 3 days. The inhibitory effect of D-allose on cancer cell proliferation was shown from day 1 and became more significant at day 5, in contrast to untreated cells. Furthermore, studies on the concentration effect of D-allose indicated that D-allose inhibits cells proliferation in a dose-dependent manner
Name Type Language
PSICOSE, DL-
Systematic Name English
DL-PSICOSE
Systematic Name English
ERYTHROHEXULOSE
Common Name English
PSEUDOFRUCTOSE
Common Name English
PSICOSE
Systematic Name English
ALLULOSE
Common Name English
RIBO-2-HEXULOSE
Common Name English
PSICOSE [INCI]
Common Name English
ALLULOSE [USP-RS]
Common Name English
Code System Code Type Description
FDA UNII
KRF88IOA7T
Created by admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
PRIMARY
CAS
23140-52-5
Created by admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
PRIMARY
CHEBI
33951
Created by admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
PRIMARY
DRUG BANK
DB15087
Created by admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
PRIMARY
PUBCHEM
90008
Created by admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
PRIMARY
RS_ITEM_NUM
1013115
Created by admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
PRIMARY
EPA CompTox
DTXSID901018792
Created by admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
PRIMARY
GRAS Notification (GRN No.)
498
Created by admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
PRIMARY
WIKIPEDIA
Psicose
Created by admin on Sat Dec 16 11:17:14 GMT 2023 , Edited by admin on Sat Dec 16 11:17:14 GMT 2023
PRIMARY